Search research articles
Contact Us
Filters
Showing results (271-280 of 436) with videos related to
Page
of 44
Sort By:
Blood Advances
|
November 19, 2020
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia
Nicholas J Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, et al.
Leukemia & Lymphoma
|
August 12, 2021
Clinical and molecular characterization of myeloid sarcoma without medullary leukemia
Hussein A Abbas, Patrick K Reville, Alexis Geppner, et al.
Acta Haematologica
|
May 12, 2020
Treating Leukemia in the Time of COVID-19
Shilpa Paul, Caitlin R Rausch, Nitin Jain, et al.
Haematologica
|
April 20, 2023
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells
Yannan Jia, Lina Han, Cassandra L Ramage, et al.
The Lancet. Haematology
|
March 28, 2024
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial
Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, et al.
Leukemia & Lymphoma
|
March 31, 2025
Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions
Eitan Kugler, Enes Dasdemir, Alex Bataller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 19, 2024
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL
Hagop Kantarjian, Nicholas J Short, Fadi G Haddad, et al.
Leukemia
|
December 19, 2025
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML
Christine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Cancer
|
April 16, 2019
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
Elias J Jabbour, Koji Sasaki, Farhad Ravandi, et al.
Blood Cancer Journal
|
April 13, 2023
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Page
of 44
Search research articles
Search
Showing results (271-280 of 436) with videos related to
Sort By:
Page
of 44
Blood Advances
|
November 19, 2020
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia
Nicholas J Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, et al.
Leukemia & Lymphoma
|
August 12, 2021
Clinical and molecular characterization of myeloid sarcoma without medullary leukemia
Hussein A Abbas, Patrick K Reville, Alexis Geppner, et al.
Acta Haematologica
|
May 12, 2020
Treating Leukemia in the Time of COVID-19
Shilpa Paul, Caitlin R Rausch, Nitin Jain, et al.
Haematologica
|
April 20, 2023
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells
Yannan Jia, Lina Han, Cassandra L Ramage, et al.
The Lancet. Haematology
|
March 28, 2024
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial
Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, et al.
Leukemia & Lymphoma
|
March 31, 2025
Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions
Eitan Kugler, Enes Dasdemir, Alex Bataller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 19, 2024
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL
Hagop Kantarjian, Nicholas J Short, Fadi G Haddad, et al.
Leukemia
|
December 19, 2025
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML
Christine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Cancer
|
April 16, 2019
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
Elias J Jabbour, Koji Sasaki, Farhad Ravandi, et al.
Blood Cancer Journal
|
April 13, 2023
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Page
of 44